Inhibition of gastric inhibitory polypeptide signaling prevents obesity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Secretion of gastric inhibitory polypeptide (GIP), a duodenal hormone, is primarily induced by absorption of ingested fat. Here we describe a novel pathway of obesity promotion via GIP. Wild-type mice fed a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous fat deposition with insulin resistance. In contrast, mice lacking the GIP receptor (Gipr(-/-)) fed a high-fat diet were clearly protected from both the obesity and the insulin resistance. Moreover, double-homozygous mice (Gipr(-/-), Lep(ob)/Lep(ob)) generated by crossbreeding Gipr(-/-) and obese ob/ob (Lep(ob)/Lep(ob)) mice gained less weight and had lower adiposity than Lep(ob)/Lep(ob) mice. The Gipr(-/-) mice had a lower respiratory quotient and used fat as the preferred energy substrate, and were thus resistant to obesity. Therefore, GIP directly links overnutrition to obesity and it is a potential target for anti-obesity drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“tirzepatide proved superior in improving glycemic control relative to treatment with semaglutide (1 mg)133, insulin degludec134, insulin glargine135,136, and insulin lispro137; importantly, with preserved efficacy and without compromising safety in subjects at risk for cardiovascular diseases136.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“While GIPR antagonism has been shown to reduce adiposity in preclinical models [64], the clinical data show tirzepatide, a dual GLP-1R/GIPR agonist, produces greater weight loss and glucose lowering than the GLP-1R agonist semaglutide alone [42], particularly at doses which comparably engage the GLP-1R [61].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
In the citing paper
“Initial reports that GIPR null mice [64] are protected from diet-induced obesity have been supported by preclinical studies in rodents and non-human primates that GIPR antagonism induces additive weight loss when combined with GLP-1R agonism [32,67], and human genetics data that loss-of-function GIPR variants associate with reduced adiposity [68].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · cited 1×
“Obese Lep ob / Lep ob mice exhibit a marked increase in adipose tissue due to hyperphagia caused by mutation of the leptin gen”
BackgroundSerum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., & Friedman, J. M. (1995) · Science · doi:10.1126/science.7624777 · Cited by 4,451
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225
Obesity and the regulation of energy balance
Spiegelman, B. M., & Flier, J. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00240-9 · Cited by 2,398
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Green, H., & Kehinde, O. (1975) · Cell · doi:10.1016/0092-8674(75)90087-2 · Cited by 1,360
Dietary fat intake does affect obesity!
Bray, G. A., & Popkin, B. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1157 · Cited by 1,123
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Cited by
Items 601–700 of 972
Cai, X., Yang, W., Zhou, L., Zhang, S., Han, X., & Ji, L. (2015) · Endocrine · doi:10.1007/s12020-015-0653-3 · Cited by 15
Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists
Gault, V. A., Hunter, K., Irwin, N., Green, B. D., Greer, B., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.03.001 · Cited by 17
Liu, X., Harada, N., Yamane, S., Kitajima, L., Uchida, S., Hamasaki, A., Mukai, E., Toyoda, K., Yamada, C., Yamada, Y., et al. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.03.022 · Cited by 20
“The receptor for GIP, differently from that for GLP-1, is expressed in adipocytes, and GIP directly facilitates energy accumulation in adipose tissue (Miyawaki et al. 2002; Naitoh et al. 2008).”
BackgroundSelf-citationBombesin and nutrients independently and additively regulate hormone release from GIP/Ins cells
Li, L., & Wice, B. M. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00346.2004 · Cited by 16
“Furthermore, mice lacking GIP receptors do not exhibit any serious detrimental phenotypes (37).”
BackgroundG protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 16
Akindehin, S., Liśkiewicz, A., Liśkiewicz, D., Bernecker, M., García‐Cáceres, C., Drucker, D. J., Finan, B., Grandl, G., Gutgesell, R. M., Hofmann, S. M., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101915 · Cited by 17
“The improvement of glycemic control in DIO Lepr-Gipr KO mice is likely attributed to the demonstrated decrease of Gipr expression in the pancreas, which is consistent with the phenotype of mice with global [23] and beta cell speci fi c [21] Gipr deletion.”
Boutari, C., Stefanakis, K., Simati, S., Guatibonza-García, V., Valenzuela‐Vallejo, L., Anastasiou, I. A., Connelly, M. A., Kokkinos, A. D., & Mantzoros, C. S. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02264-5 · Cited by 17
“A pioneering study investigating GIP-receptor deficient mice showed that weight and adiposity were physiologically influenced under normo-caloric feeding; however, a high-fat diet attenuated body weight and fat mass gain, and preserved normal insulin sensitivity [73].”
BackgroundAdipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs
Villarroya, F., Peyrou, M., & Giralt, M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00660-w · Cited by 15
“How - ever, there is an ongoing debate on whether increasing or decreasing GIPR agonism can benefit body weight and metabolism, in part based on the observation that GIPR-null mice are protected against obesity [52 ].”
ŠEBÖKOVÁ, E., Benardeau, A. M., Sprecher, U., Sewing, S., Tobalina, L., & Migliorini, C. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01207.x · Cited by 15
Incretin hormones and beta cell function in chronic pancreatitis.
Knop, F. K. (2010) · PubMed · Cited by 17
Irwin, N., Montgomery, I. A., O'Harte, F. P. M., Frizelle, P. A., & Flatt, P. R. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.179 · Cited by 14
Prasadan, K. L., Koizumi, M., Tulachan, S., Shiota, C., Lath, N. R., Paredes, J. L., Guo, P., El‐Gohary, Y., Malek, M. M., Shah, S. R., et al. (2011) · Diabetes · doi:10.2337/db09-0035 · Cited by 17
“GIPR knockout mice (20,21) did not appear to have pancreatic abnormalities that would suggest a developmental defect.”
BackgroundObesity and the Gastrointestinal Tract: You Are What You Eat
Wolfe, M. M., & Boylan, M. O. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000149 · Cited by 17
Shalaby, S. M., Zidan, H. E., Shokry, A., Saeed, J., & El-Sokkary, R. H. (2017) · The Journal of Gene Medicine · doi:10.1002/jgm.2973 · Cited by 15
“We can explain the higher GIP levels in GIPR rs2302382 and rs1800437 variants in that these variants might lead to down‐regulation of GIPR expression or activity(36,37) or be a result of chronic desensitization of GIPR leading to a positive feedback effect.(38) In accordance with our suggestion, a functional study was…”
ResultGut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity
Will, S., Hornigold, D. C., Baker, D. J., Coghlan, M. P., Mesquita, M., Trevaskis, J. L., & Naylor, J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.010 · Cited by 16
Using the Lymph Fistula Rat Model to Study Incretin Secretion
Yoder, S. M., Kindel, T. L., & Tso, P. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00008-4 · Cited by 16
“In fact, mice lacking the receptor for GIP are resistant to diet-induced obesity (Miyawaki et al., 2002; Zhou et al., 2005), making inhibition of signaling through the GIP receptor a potentially attractive target for antiobesity therapy.”
BackgroundQuiñones, M., Fernø, J., Diéguez, C., Nogueiras, R., & Al–Massadi, O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1583642 · Cited by 14
“diminish GIP activity, such as GIPR knockout mice [87], GIP antagonism [88–91] or passive immunoneutralization against GIP [92], attenuated the development of obesity.”
BackgroundHinke, S. A., Lynn, F. C., Ehses, J. A., Pamir, N., Manhart, S., Kühn‐Wache, K., Rosche, F., Demuth, H.-U., Pederson, R. A., & McIntosh, C. H. S. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-47920-6_35 · Cited by 14
Yamane, S., & Harada, N. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12942 · Cited by 14
Roell, W. C., Alsina‐Fernandez, J., Qu, H., Coşkun, T., Benson, C., Haupt, A., Kelly, R. P., O’Farrell, L. S., Sloop, K. W., Steele, J. P., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102298 · Cited by 13
“These findings suggest that long-acting GIPR agonism can produce weight loss in humans, providing clarity as to whether chronic GIPR agonism would be obesogenic, weight reducing, or weight neutral in humans [21 — 26].”
Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease
Sangwung, P., Ho, J. D., Siddall, T., Lin, J., Tomás, A., Jones, B. J., & Sloop, K. W. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00371.2023 · Cited by 15
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
d’Ávila, M., Hall, S., & Horváth, T. L. (2024) · Endocrinology · doi:10.1210/endocr/bqae128 · Cited by 14
Nakamura, T., Tanimoto, H., Okamoto, M., Takeuchi, M., Tsubamoto, Y., & Noda, H. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s297353 · Cited by 13
Self-citationGao, Z., Yang, J., Liang, Y., Yang, S., Zhang, T., Gong, Z., & Li, M. (2022) · Obesity Surgery · doi:10.1007/s11695-022-05959-4 · Cited by 15
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
Incretins and bone: friend or foe?
Mabilleau, G. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.007 · Cited by 14
Wang, T., Ma, X., Tang, T., Higuchi, K., Peng, D., Zhang, R., Chen, M., Yan, J. Y., Wang, S., Yan, D., et al. (2017) · Nutrition and Diabetes · doi:10.1038/nutd.2017.28 · Cited by 13
Effect of hormone therapy on the enteroinsular axis
Sztefko, K., Rogatko, I., Milewicz, T., Krzysiek, J., Tomasik, P., & Szafran, Z. (2005) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000172266.47820.43 · Cited by 15
“GIP is a key promoter of b-cell hyperplasia and hyperinsulinemia, so the ablation of GIP signaling or lowering of GIP levels could be one of the factors preventing obesity.(35,36) The present data clearly indicate that HT has a positive influence on carbohydrate metabolism via a mechanism involving changes in gut horm…”
BackgroundGuldstrand, M., Åhrén, B., Näslund, E. B., Holst, J. J., & Adamson, U. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01089.x · Cited by 13
Self-citationSasaki, Y., Takeda, H., SATO, T. A., Orii, T., Fujishima, S., Nagino, K., Nishise, S., Saito, H., Tanaka, Y., & Kawata, S. (2011) · Metabolism · doi:10.1016/j.metabol.2011.01.007 · Cited by 13
“Double-homozygous mice (GIPR, Lep/Lep) exhibit reduced weight gain and decreased adiposity [16].”
BackgroundInfluentialIrwin, N., Montgomery, I. A., & Flatt, P. R. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114511005228 · Cited by 13
“Although unlikely based on present data((28,29)), immunisation against GIP may also affect circulating glucagon and pancreatic a-cell function.”
Gut Hormones and Related Concepts
Bloomgarden, Z. T. (2006) · Diabetes Care · doi:10.2337/dc06-zb10 · Cited by 13
“Several DPP-IV–resistant GIP analogs have been produced, some retaining biological activity, with studies showing that [D-ALA(2)]GIP1– 42 improves glucose tolerance in the VDF rats (1).”
BackgroundIncretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice
McMorrow, H. E., Cohen, A. B., Lorch, C. M., Hayes, N. W., Fleps, S. W., Frydman, J. A., Xia, J. L., Samms, R. J., & Beutler, L. R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186652 · Cited by 12
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
Douros, J. D., Mowery, S. A., & Knerr, P. J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113812 · Cited by 12
Zhou, J., Zheng, H., Irwin, N., Berthoud, H., & Ye, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134728 · Cited by 13
“Inhibition of GIP activity by GIP-receptor gene knockout partially prevented diet-induced obesity in mice [18], suggesting that a decrease in GIP activity may lead to weight loss.”
BackgroundISHII, S., Osaki, N., & Shimotoyodome, A. (2016) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.62.40 · Cited by 12
Kheder, M. H., Sillence, M. N., Bryant, L. M., & de Laat, M. A. (2017) · Journal of Animal Science · doi:10.2527/jas.2017.1468 · Cited by 12
van Olst, N., Meiring, S., de Brauw, M., Bergman, J. J. G. H. M., Nieuwdorp, M., van der Peet, D. L., & Gerdes, V. E. A. (2020) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2020.03.003 · Cited by 13
Silvaroli, J. A., Plau, J., Adams, C. H., Banerjee, S., Widjaja‐Adhi, M. A. K., Blaner, W. S., & Golczak, M. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100054 · Cited by 12
“Importantly, the elevated levels ofGIPhavebeen reported indiet-induced obesemice as well as patients with type 2 diabetes (35, 36).”
BackgroundEdwards, K. L., Prendergast, L. A., Kalfas, S., Sumithran, P., & Proietto, J. (2022) · Obesity · doi:10.1002/oby.23404 · Cited by 12
Takahashi, H., Nakajima, A., Matsumoto, Y., Mori, H., Inoue, K., Yamanouchi, H., Tanaka, K., Tomiga, Y., Miyahara, M., Yada, T., et al. (2022) · Food & Nutrition Research · doi:10.29219/fnr.v66.7870 · Cited by 12
“A deficiency of the GIP receptor in mice causes lower glucose uptake by adipocytes under high-fat diet-feeding conditions and resistance to high-fat diet-induced obesity (40, 41).”
BackgroundElias, K., Webb, D., Tartera, H. O. D., Hellström, P. M., & Sundbom, M. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.08.010 · Cited by 13
Tirzepatide for Weight Loss: Can Medical Therapy “Outweigh” Bariatric Surgery?
Novograd, J., Mullally, J. A., & Frishman, W. H. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000515 · Cited by 12
“Interestingly, GIP has long been considered an obesogenic hormone as data showed that mice with GIPR deficiency gained less body weight and fat mass when fed a high fat diet.(25) Data from additional studies have supported this notion with findings that obese subjects exhibit elevated fasting GIP levels and amplified…”
BackgroundTanaka, K., Takiguchi, S., Miyashiro, I., Hirao, M., Yamamoto, K., Imamura, H., Yano, M., Mori, M., & Doki, Y. (2013) · Surgery · doi:10.1016/j.surg.2013.08.008 · Cited by 13
Hormone-based therapies in the regulation of fuel metabolism and body weight
Kesty, N. C., Roth, J. D., & Maggs, D. G. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.11.1733 · Cited by 13
“In preclinical models, administration of GIP did not affect food intake [81] ; however, Lep ob /Lep ob mice (a mouse model of obesity) lacking GIP receptors appear to be resistant to high-fat-diet-induced obesity [82] .”
BackgroundO'Harte, F. P. M., Hunter, K., Gault, V. A., Irwin, N., Green, B. D., Greer, B., Harriott, P., Bailey, C. J., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00391.2006 · Cited by 14
“Recent studies using GIP receptor (GIP-R) knockout mice demonstrated a phenotype associated with intolerance and diminished insulin secretion (29).”
BackgroundRebirth of the Incretin Concept: Its conception and early development
Marks, V. (2017) · Peptides · doi:10.1016/j.peptides.2017.08.002 · Cited by 12
Lee, E., Miedzybrodzka, E. L., Zhang, X., Hatano, R., Miyamoto, J., Kimura, I., Fujimoto, K., Uematsu, S., Rodríguez‐Cuenca, S., Vidal‐Puig, A., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184448 · Cited by 14
“A connection between obesity and GIP has been reported: Plasma GIP levels in obese humans are increased [4], and GIPR knockout mice are resistant to high-fat diet (HFD)-induced obesity [5].”
BackgroundThe Enteroendocrine System in Obesity
Miedzybrodzka, E. L., Reimann, F., & Gribble, F. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_582 · Cited by 12
Joo, E., Muraoka, A., Hamasaki, A., Harada, N., Yamane, S., Kondo, Y., Suzuki, K., Nasteska, D., Shibue, K., Harada, T., et al. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12289 · Cited by 12
“Previous reports have established the crucial role of GIP in linking overnutrition to obesity 43,44 .”
Intestinal FFA3 mediates obesogenic effects in mice on a Western diet
Lednovich, K., Nnyamah, C., Gough, S., Priyadarshini, M., Xu, K., Wicksteed, B. L., Mishra, S. P., Jain, S., Zapater, J. L., Yadav, H., et al. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00016.2022 · Cited by 12
Chen, T., Sun, T., Bian, Y., Pei, Y., Feng, F., Chi, H., Li, Y., Tang, X., Sang, S., Du, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01456 · Cited by 11
Stensen, S., Krogh, L. S. L., Sparre‐Ulrich, A. H., Dela, F., Hartmann, B., Vilsbøll, T., Holst, J. J., ROSENKILDE, M. M., Christensen, M., Gasbjerg, L. S., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14736 · Cited by 11
“Blood samples for analysis of plasma/serum glucose, glucagon, total GIP, total GLP-1, GIP(3-30)NH2, C-peptide, insulin, paracetamol, and lipids, as well as the SAT biopsies, were handled as previously described.”
BackgroundMethodSelf-citationHaspula, D., & Cui, Z. (2023) · Cells · doi:10.3390/cells12131801 · Cited by 14
Goldenberg, R., Teoh, H., & Verma, S. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001084 · Cited by 11
“Notwithstanding promising incretin effects in rats [7], glucose-dependent insulinotropic polypeptide (GIP)was for a long time the ‘forgotten incretin’ deemed to have limited therapeutic potential because of poor efficacy [8] and the notion that it was obesogenic as it favoured triglyceride storage in the adipose tissu…”
BackgroundTian, J. ‐., Wang, Y., Lin, N., Guo, Y., Sun, S., & Zou, D.-C. (2010) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2010.02400.x · Cited by 12
GIPR Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine
Ono, S., Suzuki, Y., Fukui, N., Sawamura, K., Sugai, T., Watanabe, J., Tsuneyama, N., & Someya, T. (2014) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.13120389 · Cited by 11
Food Intake Affects Sperm-Egg Fusion Through the GIP/PSG17 Axis in Mice
Shimizu, T., Sato, T. K., Tsukiyama, K., Fujita, H., Kato, S., Hoizumi, M., Shirasawa, H., Narita, T., Terada, Y., Seino, Y., et al. (2017) · Endocrinology · doi:10.1210/en.2016-1861 · Cited by 11
Self-citationHNF4α is a novel regulator of intestinal glucose-dependent insulinotropic polypeptide
Girard, R., Darsigny, M., Jones, C. M., Maloum-Rami, F., Gélinas, Y., Carpentier, A. C., Laplante, M., Perreault, N., & Boudreau, F. (2019) · Scientific Reports · doi:10.1038/s41598-019-41061-z · Cited by 11
Incretins today: multiple effects and therapeutic potential
Васильевна, Ц. О., Васильевна, В. В., & As, A. (2019) · Diabetes Mellitus · doi:10.14341/dm9841 · Cited by 22
Kondo-Ando, M., Seino, Y., Morikawa, R., Kana, N., Todoroki, H., Kawakami, T., Asada, Y., Yoshimoto, R., Tanaka, C., Okamoto, K., et al. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107415 · Cited by 11
Self-citationMohr, A. E., Minicucci, O., Long, D., Miller, V. J., Keller, A., Sheridan, C., O’Brien, G., Ward, E. G., Schuler, B., Connelly, S., et al. (2021) · Foods · doi:10.3390/foods10030537 · Cited by 11
“GIP has been proposed to stimulate efficient fat deposition [38,39], whereas inhibition of GIP signaling increases fat oxidation and energy expenditure, as well as reduces high-fat diet-induced obesity in mice [40,41].”
BackgroundSelf-citationBoer, G. A., Hunt, J. E., Gabe, M. B. N., Windeløv, J. A., Sparre‐Ulrich, A. H., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15894 · Cited by 13
“Furthermore, GIP receptor knockout (GIP receptor KO, GIPR / ) mice are resistant to diet-induced obesity (Miyawaki et al., 2002) and transgenic rescue of the GIP receptor in adipose tissue in the same mouse model counteracted this resistance (Ugleholdt et al., 2011).”
BackgroundResultSelf-citationIrwin, N., Hunter, K., & Flatt, P. R. (2008) · Peptides · doi:10.1016/j.peptides.2008.01.006 · Cited by 11
“Thus, evidence is now accumulating to suggest a possible role for inhibition of GIP signaling in the alleviation of obesity [15,26,33].”
Hiperplasia adrenal macronodular independente de ACTH (AIMAH): aspectos clínicos e moleculares
Antonini, S. R. R., Fragoso, M. C. B. V., & Lacroix, A. (2004) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302004000500006 · Cited by 19
Relling, A. E., Crompton, L. A., Loerch, S. C., & Reynolds, C. K. (2014) · Journal of Dairy Science · doi:10.3168/jds.2013-7574 · Cited by 11
“Using models with GIP receptor knockout mice, Miyawaki et al. (2002), reported that with the same energy intake, the knockout mice were less efficient in terms of dietary energy utilization compared with control wild-type mice.”
Gastric inhibitory polypeptide is the major insulinotropic factor in K(ATP) null mice
Tsukiyama, K., Yamada, Y., Miyawaki, K., Hamasaki, A., Nagashima, K., Hosokawa, M., Fujimoto, S., Takahashi, A., Toyoda, K., Toyokuni, S., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510407 · Cited by 11
“Since GIP receptors are also expressed in the small intestine and in insulin-target tissues such as adipocytes ( 22 ), we investigated glucose uptake by the small intestine using everted jejunal rings in vitro.”
MethodSelf-citationBoylan, M. O., Jepeal, L. I., & Wolfe, M. M. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00535.2005 · Cited by 14
“Although these mice exhibit transient mild elevations in postprandial glucose levels, it does not appear to affect the overall health of the animals (35).”
BackgroundFeng, X., Liu, H., Li, Z., Carughi, A., & Ge, S. (2019) · Frontiers in Nutrition · doi:10.3389/fnut.2019.00186 · Cited by 11
“Increased postprandial GIP responses have been reported in patients with type 2 diabetes and recent findings implicate GIP as a “diabetogenic” hormone (25, 28).”
BackgroundCurrent Approaches in Diabetes Treatment and Other Strategies to Reach Normoglycemia
Sirhan, W., & Piran, R. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200716113813 · Cited by 13
Sleeve Gastrectomy and Transit Bipartition
Santoro, S., Klajner, S., & Sampaio, R. C. (2014) · Springer eBooks · doi:10.1007/978-3-319-13126-9_5 · Cited by 13
“Enhanced secretion of GIP directly links overnutrition to obesity in general (Miyawaki et al. 2002), and to visceral obesity in particular (Oben et al.”
BackgroundInfluentialYasuda, T., Harada, N., Hatoko, T., Ichimura, A., Ikeguchi, E., Murata, Y., Wada, N., Kiyobayashi, S., Yamane, S., Hirasawa, A., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00329.2022 · Cited by 11
Green, C., Zaman, V., Blumenstock, K., Banik, N. L., & Haque, A. (2025) · Biomedicines · doi:10.3390/biomedicines13010132 · Cited by 13
“In a study performed on whether the inhibition of GIP signaling prevents obesity, researchers found that an excessive accumulation of fat allows for the hypersecretion of GIP [47,48].”
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Yammine, L., Picatoste, B., Abdullah, N., Leahey, R. A., Johnson, E. F., Gómez-Banoy, N., Rosselot, C., Wen, J., Hossain, T., Goncalves, M. D., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101831 · Cited by 10
“Our results therefore link hypersensitivity to GIP with reduced weight, which contrasts with GIPR whole body knockout mice that are resistant to diet-induced obesity [67; 68].”
ResultMatsuo, T., Kusunoki, Y., Katsuno, T., Ikawa, T., Akagami, T., Murai, K., Miuchi, M., Miyagawa, J., & Namba, M. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.002 · Cited by 12
Review: Bariatric surgery: to treat diabesity
Flatt, P. R., Day, C., & Bailey, C. J. (2009) · The British Journal of Diabetes · doi:10.1177/1474651409103927 · Cited by 11
Obesity, longevity, quality of life
Click, R. E. (2010) · Virulence · doi:10.4161/viru.1.6.13803 · Cited by 10
Hosoda, Y., Okahara, F., Mori, T., Deguchi, J., Ota, N., Osaki, N., & Shimotoyodome, A. (2017) · Food & Nutrition Research · doi:10.1080/16546628.2017.1361778 · Cited by 10
“GIPR-ablated mice exhibit high fat utilization and resistance to high-fat induced obesity [21,22].”
BackgroundGut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
Zhang, S., Xu, H., Jiang, E., Akhatayeva, Z., Jiang, F., Song, E., Pan, C., Chen, H., & Lan, X. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.887520 · Cited by 11
“Wildtype mice fed a high-fat diet showed high secretion of GIP and extreme visceral and subcutaneous fat deposition and insulin resistance (32).”
BackgroundLeiu, K. H., Poppitt, S. D., Miles-Chan, J. L., & Sequeira, I. R. (2022) · Nutrients · doi:10.3390/nu14224873 · Cited by 10
“This has been proposed due to changes in gastrointestinal hormone secretion that regulates adiposity [88] or alteration in fatty acid transport proteins that lower fatty acid update in the pancreas [89], amongst other potential mechanisms.”
BackgroundEnya, M., Horikawa, Y., Iizuka, K., & Takeda, J. (2014) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2014.07.009 · Cited by 11
“In addition, GIP promotes lipid accretion and resistin secretion from adipocytes, leading to progressive impairment of insulin action following long-term GIP administration in rodents fed a high-fat diet [5].”
BackgroundInfluentialMin, X., Yie, J., Wang, J., Chung, B. C., Huang, C.-S., Xu, H., Yang, J., Deng, L., Lin, J., Chen, Q., et al. (2020) · mAbs · doi:10.1080/19420862.2019.1710047 · Cited by 10
“diet, they are resistant to high fat diet-induced obesity and insulin resistance.(17) While human genetics and mouse models demonstrate that GIPR loss of function is associated with lower body weight, pharmacological evidence has been weak and controversial so far.”
BackgroundFreitas, T. B., Felix, T. L., Shriver, W., Fluharty, F. L., & Relling, A. E. (2020) · Translational Animal Science · doi:10.1093/tas/txaa009 · Cited by 10
Angevine, K., Wuescher, L. M., Andrews, K., Alexander, L., McInerney, M. F., Kieffer, T. J., & Mensah‐Osman, E. (2012) · Nutrition and Diabetes · doi:10.1038/nutd.2012.30 · Cited by 10
Inhibition of GIP signaling extends lifespan without caloric restriction
Hoizumi, M., Sato, T. K., Shimizu, T., Kato, S., Tsukiyama, K., Narita, T., Fujita, H., Morii, T., Sassa, M. H., Seino, Y., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.036 · Cited by 10
Self-citationPathogenesis of type 2 diabetes in Japan and East Asian populations: Basic and clinical explorations
Seino, Y., & Yamazaki, Y. (2025) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.101.009 · Cited by 11
Self-citationThe evolution of the therapeutic concept ‘GIP receptor antagonism’
Koefoed-Hansen, F., Helsted, M. M., Kizilkaya, H. S., Lund, A., ROSENKILDE, M. M., & Gasbjerg, L. S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1570603 · Cited by 9
“However, in 2006 it became clear that GIP( At the same time, in 2002, Gipr knockout mice were found to be protected against both obesity and insulin resistance induced by high-fat feeding (53).”
InfluentialDavies, I., & Tan, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203911 · Cited by 10
“The landmark finding for the theory of GIP’s promotion of obesity came in 2002 by Miyawaki et al who showed that GIPR knockout (KO) mice were protected from high-fat diet (HFD) induced obesity [30].”
BackgroundLee, S., Chung, M. J., Ahn, M., Park, H. J., Wang, E. K., Guon, T., Kee, H. J., Ku, C. R., & Na, K. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122336 · Cited by 9
Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion
Xu, Y., Michalowski, C. B., Koehler, J. A., Darwish, T., Guccio, N., Alcaino, C., Domingues, I., Zhang, W., Marotti, V., Hul, M. V., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq9909 · Cited by 10
“Many studies have highlighted the key role of regulating EEC secretion ability in improving metabolic dysfunction ( 15 , 56 ).”
Barbosa-Yañez, R. L., Markova, M., Dambeck, U., Honsek, C., Machann, J., Schüler, R., Kabisch, S., & Pfeiffer, A. F. H. (2019) · Peptides · doi:10.1016/j.peptides.2019.170237 · Cited by 9
Wolfe, M. M., Apovian, C. M., & Boylan, M. O. (2023) · Obesity · doi:10.1002/oby.23758 · Cited by 9
“Finally, the current studies corroborate earlier studies [4, 5] and provide evidence that the disruption of GIP signaling using a specific GIP mAb might ultimately prove useful as a modality for treating obesity and comorbidities.”
BackgroundResultInfluentialThe Genetic Determinants of Common Obesity-Susceptibility
Loos, R. J. F. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0965-6_10 · Cited by 11
Interactions between the Gut, the Brain and Brown Adipose Tissue Function
van den Beukel, J. C., & Grefhorst, A. (2014) · Frontiers of hormone research · doi:10.1159/000358320 · Cited by 9
Franklin, Z. J., McDonnell, B. M., Montgomery, I. A., Flatt, P. R., & Irwin, N. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01401.x · Cited by 10
“basal and meal-stimulated insulin concentrations [10,12,13].”
BackgroundEnergy Balance, Myostatin, and GILZ: Factors Regulating Adipocyte Differentiation in Belly and Bone
Shi, X., Hamrick, M. W., & Isales, C. M. (2007) · PPAR Research · doi:10.1155/2007/92501 · Cited by 11
“[87], demonstrates that although normal mice fed a high-fat diet gained weight, GIP receptor knockout mice were protected from the large weight gain associated with this diet.”
BackgroundBueter, M., & le Roux, C. W. (2009) · Proceedings of The Nutrition Society · doi:10.1017/s0029665109001256 · Cited by 9
“GIP-receptor-knock-out mice have lower adipocyte mass and display a resistance to dietinduced obesity((90)).”
Background
Metadata
- Authors
- Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., Hiai, H., Mizunoya, W., Fushiki, T., Holst, J. J., Makino, M., Tashita, A., Kobara, Y., Tsubamoto, Y., Jinnouchi, T., Jomori, T., & Seino, Y.
- Affiliations
- Kyoto University (JP)
- University of Copenhagen (DK)
- Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) (JP)
- Corresponding author
- Seino, Yutaka
- Venue
- Nature Medicine
- Published
- 2002-06-17
- Volume
- 8
- Issue
- 7
- Pages
- 738-742
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2102392334
- Cited by
- 963
- References
- 24
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 64 · 2023: 45 · 2022: 38 · 2021: 39 · 2020: 37 · 2019: 66 · 2018: 39 · 2017: 45 · 2016: 38 · 2015: 42 · 2014: 44 · 2013: 38 · 2012: 38
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, obesity, insulin resistance, high-fat diet, adiposity, respiratory quotient, fat oxidation, anti-obesity drugs, overnutrition
- MeSH terms
- Adipose Tissue, Animals, Body Weight, Crosses, Genetic, Dietary Fats, Gastric Inhibitory Polypeptide, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.